Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

'Don't panic': WHO says safety systems working as AstraZeneca shots paused

Published 15/03/2021, 17:35
Updated 15/03/2021, 17:55
© Reuters. FILE PHOTO: A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine"  in this illustration

GENEVA/ZURICH (Reuters) - The World Health Organization's director general said on Monday that systems meant to protect public health were working, as several countries suspended use of AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine to investigate possible side-effects.

"This does not necessarily mean these events are linked to COVID-19 vaccination, but it's routine practice to investigate them, and it shows that the surveillance system works and that effective controls are in place," Tedros Adhanom Ghebreyesus said during a virtual media briefing.

A WHO advisory committee plans to meet on Tuesday to discuss the vaccine, which Germany, France and Italy said on Monday they were pausing after several countries reported serious conditions in people who had received the shot.

Denmark and Norway had stopped giving the shot last week after reporting isolated cases of blood clots, bleeding or a low platelet count. Iceland and Bulgaria followed suit and Ireland and the Netherlands announced suspensions on Sunday.

Even so, the top WHO scientist reiterated on Monday that there had been no documented deaths linked to COVID-19 vaccines.

"We do not want people to panic," WHO chief scientist Soumya Swaminathan told the briefing, adding that no association had so far been found between the "thromboembolic events" reported in some countries and COVID-19 shots.

Even as some countries suspend AstraZeneca's shot, others are continuing its use as the WHO and other bodies say the benefits continue to outweigh any risks.

The United Kingdom, where the AstraZeneca vaccine was developed in partnership with Oxford University, says it has no concerns, while the drugmaker has said a review of safety data has shown no evidence of an increased risk of blood clots.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.